Robert Lustig, MD: NAFLD Secrets: Key Markers and Risk Factors #LiverHealth #TrendingTopics #shorts
A short interview clip in which an interviewer asks Robert Lustig which biomarkers clinicians should watch to predict non-alcoholic fatty liver disease (NAFLD). Lustig states that certain biomarkers can indicate disease development before clinical onset; the interviewer specifically mentions insulin levels as an example. The clip centers on fasting/insulin-related biomarkers as early indicators of NAFLD.
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet